(Q58053452)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

review article

1 reference

title

Insulin glargine and its role in glycaemic management of Type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Melanie Davies

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

J Jarvis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

M A Elrishi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

language of work or name

English

0 references

publication date

1 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

1099-1110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Insulin analogues and their potential in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Pancreatic beta-cell growth and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Effects of mixing glargine and short-acting insulin analogs on glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Survey of glargine use in 115 pregnant women with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.8.1099

10.1517/17425255.4.8.1099

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18680444%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference